SAC StudioPotent and cheap, and closer to the studied chemistry than the standardization line first suggested
Toniiq is concentrated and cheap per cap: 600 mg extract standardized to 5% salidroside AND 3% rosavins (30 mg / 18 mg per serving), GMP-made, batch-tested, 120 count. The 3% rosavins figure lines up with the classic SHR-5 fatigue trials' roughly 3% rosavins standard — but the 5% salidroside is about five times the SHR-5 extract's ~1%. It's a legitimate, dual-standardized product; the salidroside load is just far beyond what the human trials tested.
The label states both markers: 3% rosavins (18 mg) — matching the SHR-5 fatigue-trial ratio almost exactly — and 5% salidroside (30 mg), about five times the trial extract's ~1%. That's a genuine match on the primary studied compound, not the salidroside-only, no-rosavins profile an earlier version of this review described. What's left is scale: five times the studied salidroside dose layered on top, which the trials never tested.
600 mg total extract (18 mg rosavins, 30 mg salidroside) is a larger single dose than the SHR-5 trials used, and the 5% salidroside load is well beyond the studied ~1%. The rosavins side now checks out; the overall dose and the added salidroside are still the harder-to-map pieces.
GMP-certified USA facility with third-party batch testing. Reasonable, though public COA transparency is lighter than NOW or Thorne.
A standard capsule of concentrated extract. The concentrated 5% salidroside extract is more stimulating for some users; start cautiously and take early to avoid sleep disruption.
120 caps at ~$20 is a strong per-cap price and a long supply — value is Toniiq's real strength.
“Higher salidroside means a stronger, more effective rhodiola”
Salidroside is a bioactive of interest, but the human fatigue evidence used rosavins-forward SHR-5, not high-salidroside extracts. 'Stronger' on one compound doesn't equal closer to the studied effect (Ishaque 2012, PMID 22643043).
“Toniiq matches the extract used in the classic rhodiola trials”
The trials used SHR-5 standardized to ~3% rosavins / 1% salidroside; Toniiq's label states 3% rosavins (18 mg) — matching that ratio — plus 5% salidroside (30 mg), about five times the SHR-5 level. That's a partial match, not a mismatch: the primary rosavins marker lines up, but the added salidroside load is untested at this ratio (Darbinyan 2000, PMID 11081987).
An earlier version of this review said Toniiq was standardized to 5% salidroside with "no stated rosavins." The Supplement Facts panel reads Salidrosides 30 mg (5%) AND Rosavins 18 mg (3%) per 600 mg (2-capsule) serving — the same ~3% rosavins ratio the SHR-5 fatigue trials used, plus a much larger salidroside dose than those trials tested. We re-read the label on Sep 7, 2026 and corrected the Standardization spec, the claims table, the tldr, the badge, and the Standardization & Extract Match score (5 → 7.5; overall 6.2 → 6.9, verdict unchanged: consider).
There are two schools of rhodiola standardization: rosavins-forward (the SHR-5 trial extract, ~3% rosavins/~1% salidroside) and salidroside-forward extracts that skip rosavins. Toniiq's label shows it isn't the second kind — it states 3% rosavins (18 mg) alongside 5% salidroside (30 mg), so it clears the SHR-5 rosavins bar while adding a much larger salidroside dose on top.
On testing and value Toniiq is respectable, and on standardization it's closer to the studied profile than an earlier version of this review credited: the label's 3% rosavins matches the SHR-5 ratio. The remaining gap is scale — 5% salidroside is about five times what the trials used, which is untested territory, not a wrong compound.
Toniiq's label actually clears the SHR-5 rosavins bar (3%, 18 mg) that Life Extension, Thorne, and NOW also target — it just adds about five times more salidroside (5% vs ~1%) on top, which the fatigue trials never tested. If you want the closest literal match to the trial extract with no salidroside variable, those lower-salidroside 3%/1% picks are the more direct match; if you're fine with (or want) extra salidroside, Toniiq gives you the studied rosavins ratio plus a bonus.
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
The rosavins-forward 3%/1% profile the fatigue trials actually used, at the right dose — the studied-effect pick.
See it on the list →Correct min 3% rosavins / 1% salidroside from an auditable brand if you want the studied ratio at good value.
See it on the list →Used SHR-5 standardized to ~3% rosavins / 1% salidroside — a rosavins-forward profile, not a high-salidroside extract.
Fatigue evidence is tied to specific standardized extracts; extrapolating to differently-standardized products is not supported.
